The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Apogee Therapeutics Inc shares valued at $133,525,000 were sold by Fairmount Funds Management LLC on Jan 22 ’26. At $76.30 per share, Fairmount Funds Management LLC sold 1,750,000 shares. The insider’s holdings dropped to 298,647 shares worth approximately $23.85 million following the completion of this transaction.
Also, Fairmount Healthcare Fund II L purchased 1,750,000 shares, netting a total of over 133,525,000 in proceeds.
Before that, HENDERSON MICHAEL THOMAS had sold 20,000 shares from its account. In a trade valued at $1,622,159, the Chief Executive Officer traded Apogee Therapeutics Inc shares for $81.11 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $95.27 million.
As published in a research note from RBC Capital Mkts on January 22, 2026, Apogee Therapeutics Inc [APGE] has been rated down from an Outperform to a Sector perform and the price target has been revised to $83. Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in early January. As of December 17, 2025, Stephens has initiated its “an Overweight” rating for APGE. Earlier on December 10, 2025, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for APGE stock.
Analyzing APGE Stock Performance
On last trading session, Apogee Therapeutics Inc [NASDAQ: APGE] plunged -2.50% to $79.86. The stock’s lowest price that day was $77.61, but it reached a high of $81.525 in the same session. During the last five days, there has been a drop of approximately -3.12%. Over the course of the year, Apogee Therapeutics Inc shares have jumped approximately 102.38%.
Is Apogee Therapeutics Inc subject to short interest?
Stocks of Apogee Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.77 million shares to 8.66 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.9 million shares. A jump of 8.84% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.92 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.92.
Which companies own the most shares of Apogee Therapeutics Inc (APGE)?
In terms of Apogee Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 109.5 in the next 12 months, up nearly 33.68% from the previous closing price of $81.91. Analysts anticipate Apogee Therapeutics Inc stock to reach 137 by 2026, with the lowest price target being 83. On November 03, 2025, Craig Hallum assigned a price target of “a Buy” to the stock and initiated coverage with a $109.
